Alzheimer’s Drug Assessment In U.K. Will Turn To Select Populations
This article was originally published in The Pink Sheet Daily
Executive Summary
Comments from stakeholders prompt National Institute for Clinical Excellence request for additional evidence on clinical efficacy of memantine and acetylcholinesterase inhibitors in specific patient populations. Preliminary cost effectiveness appraisal had recommended against use of the Alzheimer’s drugs.